Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock Has Average Target Price of $122.00

Key Points

• Analyst sentiment is broadly positive: Monopar has a “Moderate Buy” consensus from 10 analysts, with an average 12-month price target of $122. Six analysts rate it Buy and one Strong Buy, while two rate it Hold and one Sell.
• Recent results modestly beat expectations: The company reported a quarterly loss of $0.62 per share, slightly better than the $0.64 loss analysts expected.
• Insiders have been selling shares: Company insiders sold 51,920 shares worth about $4.53 million in the last quarter; insiders retain 9.7% ownership.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $122.00.

Several research firms have commented on MNPR. Cantor Fitzgerald downgraded shares of Monopar Therapeutics from an "overweight" rating to a "neutral" rating and increased their target price for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. BTIG Research boosted their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Barclays reiterated an "overweight" rating and set a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Finally, HC Wainwright increased their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd.

Monopar Therapeutics Stock Up 4.2%

MNPR stock opened at $72.81 on Thursday. The company has a market capitalization of $488.56 million, a price-to-earnings ratio of -33.55 and a beta of 1.62. Monopar Therapeutics has a 12 month low of $50.07 and a 12 month high of $124.82. The firm has a 50 day moving average of $88.66 and a two-hundred day moving average of $77.40.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. On average, research analysts expect that Monopar Therapeutics will post -2.98 EPS for the current fiscal year.

Insider Buying and Selling

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 2,891 shares of the company's stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $71.26, for a total transaction of $206,012.66. Following the completion of the sale, the director owned 1,199 shares of the company's stock, valued at $85,440.74. This represents a 70.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher M. Starr sold 8,400 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director owned 5,173 shares in the company, valued at approximately $406,080.50. This trade represents a 61.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 51,920 shares of company stock valued at $4,527,913 in the last quarter. Company insiders own 9.70% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of institutional investors have recently modified their holdings of MNPR. Sei Investments Co. lifted its stake in shares of Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company's stock worth $415,000 after buying an additional 656 shares during the last quarter. Your Advocates Ltd. LLP bought a new stake in shares of Monopar Therapeutics during the 1st quarter worth $183,000. The Manufacturers Life Insurance Company acquired a new position in Monopar Therapeutics in the 1st quarter valued at $250,000. Bank of New York Mellon Corp grew its stake in Monopar Therapeutics by 21.2% in the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company's stock valued at $4,307,000 after buying an additional 13,761 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its stake in Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock valued at $14,480,000 after buying an additional 30,370 shares during the last quarter. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company's research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar's pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.